Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Convertible Note - II | Alive

Total Raised


About Metabolomic Diagnostics

Metabolomic Diagnostics is an early-stage medical diagnostics company dedicated to improving women's health. The company's focus is on developing screening tests which can assess, long before the appearance of clinical symptoms, a women's risk of developing compliance during pregnancy.

Metabolomic Diagnostics Headquarters Location

Hoffmann Park Inchera, Little Island

Cork, T45YX04,


+353 21 4510263

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Metabolomic Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Metabolomic Diagnostics is included in 6 Expert Collections, including Women's Health & Wellness.


Women's Health & Wellness

1,476 items

Startups focused on providing products and services catering to women's health and wellbeing.


Medical Devices

8,487 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,412 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,750 items



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Health IT

7,901 items

Metabolomic Diagnostics Patents

Metabolomic Diagnostics has filed 3 patents.

The 3 most popular patent topics include:

  • Diabetes
  • Midwifery
  • Neonatology
patents chart

Application Date

Grant Date


Related Topics



Diabetes, Obstetrics, Midwifery, Neonatology, Women's health


Application Date


Grant Date


Related Topics

Diabetes, Obstetrics, Midwifery, Neonatology, Women's health



Latest Metabolomic Diagnostics News and Metabolomic Diagnostics Partner to Develop a Novel Preeclampsia Risk Screening Test

Feb 21, 2022

Biotech firm and Metabolomic Diagnostics are teaming up to develop a novel pre-eclampsia risk screening test, with plans to launch in the U.S. in late 2022. The test will be jointly developed specifically for the U.S. population, improving upon available assessments by creating a personalized risk profile for individuals. It measures a panel of biomarkers in blood that serves as early…

  • When was Metabolomic Diagnostics founded?

    Metabolomic Diagnostics was founded in 2011.

  • Where is Metabolomic Diagnostics's headquarters?

    Metabolomic Diagnostics's headquarters is located at Hoffmann Park, Cork.

  • What is Metabolomic Diagnostics's latest funding round?

    Metabolomic Diagnostics's latest funding round is Convertible Note - II.

  • How much did Metabolomic Diagnostics raise?

    Metabolomic Diagnostics raised a total of $6.21M.

  • Who are the investors of Metabolomic Diagnostics?

    Investors of Metabolomic Diagnostics include SOSV, Horizon 2020, Enterprise Ireland, Enterprise Equity and AIB Seed Capital Fund.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.